Advances in RNA therapy for the treatment of autoimmune diseases

IF 9.2 1区医学 Q1 IMMUNOLOGY

Autoimmunity reviews Pub Date : 2025-01-20 DOI:10.1016/j.autrev.2025.103753

Ying Zhang , Chenyang Zang , Manyun Mao , Mi Zhang , Zhenwei Tang , Wangqing Chen , Wu Zhu

引用次数: 0

Abstract

Autoimmune diseases (ADs) are a group of complex, chronic conditions characterized by disturbance of immune tolerance, with examples including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis. These diseases have unclear pathogenesis, and traditional therapeutic approaches remain limited. However, advances in high-throughput histology technology and scientific discoveries have led to the identification of various pathogenic factors contributing to ADs. Coupled with improvements in RNA nucleic acid-based drug synthesis, design, and delivery, RNA-based therapies have been extensively investigated for their potential in treating ADs. This paper reviews the progress in the use of miRNAs, lncRNAs, circRNAs, siRNAs, antisense oligonucleotides (ASOs), aptamers, mRNAs, and other RNA-based therapies in ADs, focusing on their therapeutic potential and application prospects, providing insights for future research and clinical treatment of autoimmune diseases.

Abstract Image

查看原文本刊更多论文

RNA治疗自身免疫性疾病的研究进展

自身免疫性疾病（ADs）是一组以免疫耐受障碍为特征的复杂慢性疾病，包括系统性红斑狼疮、类风湿性关节炎、多发性硬化症和牛皮癣。这些疾病的发病机制尚不清楚，传统的治疗方法仍然有限。然而，高通量组织学技术的进步和科学发现已经导致了各种致病因素的鉴定。加上基于RNA核酸的药物合成、设计和递送的改进，基于RNA的治疗方法在治疗ad方面的潜力得到了广泛的研究。本文综述了miRNAs、lncRNAs、circRNAs、sirna、反义寡核苷酸（ASOs）、适体、mrna、等基于rna的ad治疗方法，重点关注其治疗潜力和应用前景，为未来自身免疫性疾病的研究和临床治疗提供见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Autoimmunity reviews 医学-免疫学

CiteScore

24.70

自引率

4.40%

发文量

164

审稿时长

21 days

期刊介绍： Autoimmunity Reviews is a publication that features up-to-date, structured reviews on various topics in the field of autoimmunity. These reviews are written by renowned experts and include demonstrative illustrations and tables. Each article will have a clear "take-home" message for readers. The selection of articles is primarily done by the Editors-in-Chief, based on recommendations from the international Editorial Board. The topics covered in the articles span all areas of autoimmunology, aiming to bridge the gap between basic and clinical sciences. In terms of content, the contributions in basic sciences delve into the pathophysiology and mechanisms of autoimmune disorders, as well as genomics and proteomics. On the other hand, clinical contributions focus on diseases related to autoimmunity, novel therapies, and clinical associations. Autoimmunity Reviews is internationally recognized, and its articles are indexed and abstracted in prestigious databases such as PubMed/Medline, Science Citation Index Expanded, Biosciences Information Services, and Chemical Abstracts.